(NASDAQ: XLO) Xilio Therapeutics's forecast annual revenue growth rate of 12.71% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.97%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.99%.
Xilio Therapeutics's revenue in 2025 is $9,274,000.On average, 1 Wall Street analysts forecast XLO's revenue for 2025 to be $5,371,893,001, with the lowest XLO revenue forecast at $5,371,893,001, and the highest XLO revenue forecast at $5,371,893,001. On average, 1 Wall Street analysts forecast XLO's revenue for 2026 to be $1,119,014,920, with the lowest XLO revenue forecast at $1,119,014,920, and the highest XLO revenue forecast at $1,119,014,920.
In 2027, XLO is forecast to generate $687,668,585 in revenue, with the lowest revenue forecast at $687,668,585 and the highest revenue forecast at $687,668,585.